JADPRO 2023 BC
Advertisement
A presenter from the session shares what she hopes attendees learned about improving outcomes for patients with mBC.
Christine McGinn, MSN, APRN, ACNP-BC, spoke at JADPRO Live 2023 about improving outcomes for women with mBC.
People were more likely to engage with social media content when it featured stories related to their personal circumstances.
The program hosted meetings for Black patients with mBC and patient advocates to develop educational materials.
The phase III TROPiCS-02 study compared sacituzumab govitecan, an antibody-drug conjugate, with single-agent chemotherapy.
The conference offers critical networking and learning opportunities for oncology nurses.
To examine PROs and QOL, the researchers asked patients to complete 3 PRO tools.
The combination treatment was associated with “improved effectiveness” compared with aromatase inhibitor therapy alone.
As frontline providers, APPs need to "stay educated on the plethora of information surrounding genomic assays."
The COVID-19 pandemic "presented significant additional hurdles in an already unstable and shifting environment."
All patients had estrogen receptor-positive/HER2-negative advanced breast cancer with ECOG performance status of 0 or 1.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.